share_log

Brookline Capital Initiates Coverage On Palisade Bio With Buy Rating, Announces Price Target of $38

Brookline Capital Initiates Coverage On Palisade Bio With Buy Rating, Announces Price Target of $38

Brookline Capital开始对Palisade Bio进行覆盖,给予买入评级,并宣布目标价为38美元。
Benzinga ·  2024/11/21 06:00  · 评级/大行评级

Brookline Capital analyst Kumaraguru Raja initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $38.

Brookline Capital分析师Kumaraguru Raja开始覆盖Palisade Bio(纳斯达克:PALI),给予买入评级,并公布目标股价为38美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发